Does GLP-1 Weight Loss Plateau? What the Physiology Shows

Weight loss on a GLP-1 drug doesn't continue in a straight line forever — it slows, then flattens into a plateau. That pattern shows up plainly in the pivotal trials themselves, and it's worth understanding as expected physiology rather than a sign the drug has stopped working.

The plateau is in the trial data itself

STEP 1's headline number — roughly 15% mean weight loss with semaglutide — was measured at week 68, not at some earlier point where the curve was still climbing steeply¹. SURMOUNT-1's roughly 21% figure for tirzepatide at the top dose was measured at week 72². Both trials show the same underlying shape: rapid loss early, a decelerating rate as treatment continues, and a flattening curve as the trial's endpoint approaches. That's not incidental to how these drugs work — it's the expected trajectory.

Why it happens: the body's feedback loop

A 2024 study in the journal *Obesity*, led by a National Institutes of Health researcher, used a validated mathematical model of energy metabolism to simulate why different weight-loss interventions plateau at different points³. The model compared diet restriction, semaglutide 2.4 mg, tirzepatide 10 mg, and gastric bypass surgery. Its central finding: the body has a feedback control circuit that links weight loss to increased appetite — lose weight, and the body pushes back by making you hungrier, which is exactly the mechanism that makes plain dieting so hard to sustain. What the model found is that GLP-1 receptor agonism substantially weakens that feedback circuit compared with diet restriction alone, which is precisely why it produces a longer period of weight loss before the plateau sets in — comparable in magnitude to what gastric bypass surgery does to the same feedback loop, though surgery's overall persistent effect was still more than double that of either GLP-1 drug in the model.

What this reframes about "the drug stopped working"

If a plateau were simply the drug losing effect, you'd expect weight to start climbing back up while still on treatment at a stable dose. That's a different pattern from what's typically reported — a leveling off, not a reversal. The modeling above offers a physiological explanation for why leveling off happens even while a drug remains fully active: the feedback loop that drives hunger finds a new equilibrium at the lower body weight, and continuing the same dose maintains that equilibrium rather than continuing to push weight lower indefinitely. That's a structurally different situation from GLP-1 weight regain after stopping, where discontinuing the drug removes its suppression of that feedback loop entirely and appetite tends to increase past baseline.

What plateauing is not a reason to assume

A plateau on a stable dose is not, on its own, evidence the treatment has failed or that switching drugs is necessary. It's also not a signal to self-escalate beyond your prescribed dose — see GLP-1 dosage and titration schedules for why the approved schedule tops out where it does, and GLP-1 microdosing for the flip side of the same instinct to deviate from label dosing without evidence behind it. If your weight loss has plateaued well below what the trial averages would predict, or earlier than the roughly 68–72 week window the pivotal trials studied, that's a genuine conversation to have with your prescriber about dose, molecule, or adherence — not something to try to solve on your own.

Where this fits into the bigger picture

Between the two molecules, tirzepatide's dual-receptor mechanism appears to produce a larger and longer-sustained effect on the appetite feedback loop before plateauing, which tracks with its larger average trial weight loss — see semaglutide vs tirzepatide for the full comparison. The FDA-labeled side effects that come with staying on treatment through a plateau are covered in GLP-1 side effects, and the rest of the Desk's sourced evidence is in the research library.